A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

BACKGROUND: Approximately 70% of patients with metastatic breast cancer (MBC) develop bone metastases. Despite advances in systemic treatment options and the use of bone targeted agents in the management of bone metastases to reduce skeletal morbidity, there remains an unmet need for further treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Winter, Matthew, Coleman, Rob, Kendall, Jessica, Palmieri, Carlo, Twelves, Chris, Howell, Sacha, MacPherson, Iain, Wilson, Caroline, Purohit, Kash, Gath, Jacqui, Taylor, Christine, Eastell, Richard, Murden, Geraldine, Brown, Sarah R., Rathbone, Emma, Brown, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253642/
https://www.ncbi.nlm.nih.gov/pubmed/35800293
http://dx.doi.org/10.1016/j.jbo.2022.100442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253642/
https://www.ncbi.nlm.nih.gov/pubmed/35800293
http://dx.doi.org/10.1016/j.jbo.2022.100442

Ejemplares similares